Date published: 2025-9-9

1-800-457-3801

SCBT Portrait Logo
Seach Input

AADACL2 Inhibitors

AADACL2 inhibitors are a class of chemical compounds specifically designed to target and inhibit the function of the AADACL2 protein, which stands for Arylacetamide Deacetylase-Like 2. AADACL2 is a member of the arylacetamide deacetylase (AADAC) family of enzymes, which are involved in the hydrolysis of ester and amide bonds in various substrates. These enzymes play crucial roles in the metabolism of lipids, xenobiotics, and other bioactive molecules within the body. AADACL2, in particular, is believed to be involved in the hydrolysis of specific lipid esters, potentially influencing lipid metabolism and the processing of bioactive lipids that are important for cell signaling and homeostasis. Inhibitors of AADACL2 function by binding to the enzyme's active site, blocking its catalytic activity and preventing it from hydrolyzing its lipid substrates. This inhibition can disrupt the normal metabolic pathways that depend on AADACL2 activity, leading to the accumulation of its lipid substrates or the reduction in the levels of its hydrolyzed products. Such disruptions can have various downstream effects on cellular function, particularly in processes related to lipid metabolism, membrane dynamics, and intracellular signaling. For example, the inhibition of AADACL2 could alter the composition of cellular membranes, affect the production of signaling molecules derived from lipids, or influence the regulation of lipid storage and utilization within cells. Understanding the effects of AADACL2 inhibition provides valuable insights into the role of this enzyme in lipid metabolism and its broader implications for cellular physiology. This knowledge is essential for exploring how the regulation of lipid-processing enzymes like AADACL2 contributes to the maintenance of cellular homeostasis, the modulation of signaling pathways, and the overall balance of metabolic processes within the cell.

Items 1 to 10 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Lipase Inhibitor, THL

96829-58-2sc-203108
50 mg
$51.00
7
(1)

Lipase inhibitor, potentially affecting lipid metabolism pathways relevant to AADACL2.

Atorvastatin

134523-00-5sc-337542A
sc-337542
50 mg
100 mg
$252.00
$495.00
9
(1)

HMG-CoA reductase inhibitor, may indirectly influence lipid-related processes involving AADACL2.

Simvastatin

79902-63-9sc-200829
sc-200829A
sc-200829B
sc-200829C
50 mg
250 mg
1 g
5 g
$30.00
$87.00
$132.00
$434.00
13
(1)

Inhibits HMG-CoA reductase, potentially impacting lipid biosynthesis pathways linked to AADACL2.

Fenofibrate

49562-28-9sc-204751
5 g
$40.00
9
(1)

Activates PPARα, influencing lipid metabolism, potentially affecting AADACL2's role.

Gemfibrozil

25812-30-0sc-204764
sc-204764A
5 g
25 g
$65.00
$262.00
2
(2)

PPARα agonist, may modulate lipid processing pathways possibly involving AADACL2.

Ezetimibe

163222-33-1sc-205690
sc-205690A
25 mg
100 mg
$94.00
$236.00
12
(2)

Inhibits intestinal absorption of cholesterol, potentially impacting lipid pathways related to AADACL2.

Nicotinic Acid

59-67-6sc-205768
sc-205768A
250 g
500 g
$61.00
$122.00
1
(1)

Influences lipid metabolism, potentially impacting processes related to AADACL2.

Rosuvastatin

287714-41-4sc-481834
10 mg
$142.00
8
(0)

HMG-CoA reductase inhibitor, may influence lipid metabolism pathways involving AADACL2.

Pravastatin, Sodium Salt

81131-70-6sc-203218
sc-203218A
sc-203218B
25 mg
100 mg
1 g
$68.00
$159.00
$772.00
2
(1)

Inhibits HMG-CoA reductase, potentially affecting lipid-related functions of AADACL2.

Lovastatin

75330-75-5sc-200850
sc-200850A
sc-200850B
5 mg
25 mg
100 mg
$28.00
$88.00
$332.00
12
(1)

HMG-CoA reductase inhibitor, could indirectly impact AADACL2 activity.